231 related articles for article (PubMed ID: 16586069)
41. Anemia with impaired erythropoietin response in diabetic patients.
Thomas MC; Cooper ME; Tsalamandris C; MacIsaac R; Jerums G
Arch Intern Med; 2005 Feb; 165(4):466-9. PubMed ID: 15738380
[TBL] [Abstract][Full Text] [Related]
42. [Anaemia in chronic heart failure].
Hradec J
Vnitr Lek; 2010 Aug; 56(8):854-9. PubMed ID: 20845618
[TBL] [Abstract][Full Text] [Related]
43. Orthostatic hypotension in diabetic patients-10-year follow-up study.
Gaspar L; Kruzliak P; Komornikova A; Celecova Z; Krahulec B; Balaz D; Sabaka P; Caprnda M; Kucera M; Rodrigo L; Uehara Y; Dukat A
J Diabetes Complications; 2016; 30(1):67-71. PubMed ID: 26412028
[TBL] [Abstract][Full Text] [Related]
44. Anemia and cardiovascular disease in diabetic nephropathy.
McFarlane SI; Salifu MO; Makaryus J; Sowers JR
Curr Diab Rep; 2006 Jun; 6(3):213-8. PubMed ID: 16898574
[TBL] [Abstract][Full Text] [Related]
45. Cardiovascular risk in the young type 1 diabetes population with a low 10-year, but high lifetime risk of cardiovascular disease.
McVeigh GE; Gibson W; Hamilton PK
Diabetes Obes Metab; 2013 Mar; 15(3):198-203. PubMed ID: 22998614
[TBL] [Abstract][Full Text] [Related]
46. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease?
Chico A; Pérez A; Córdoba A; Arcelús R; Carreras G; de Leiva A; González-Sastre F; Blanco-Vaca F
Diabetologia; 1998 Jun; 41(6):684-93. PubMed ID: 9662051
[TBL] [Abstract][Full Text] [Related]
47. Screening and management of patients with early chronic kidney disease.
Rossert J; Fouqueray B
Acta Diabetol; 2004 Mar; 41 Suppl 1():S6-12. PubMed ID: 15103542
[TBL] [Abstract][Full Text] [Related]
48. [Relationship of diabetic retinopathy, nephropathy resistance of skin capillaries, hypertension and peripheral angiopathy in 868 patients with diabetes].
Zdichynec B
Cesk Oftalmol; 1977 Jan; 33(1):41-6. PubMed ID: 837456
[No Abstract] [Full Text] [Related]
49. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
[TBL] [Abstract][Full Text] [Related]
50. Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia--the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT).
Theilade S; Claggett B; Hansen TW; Skali H; Lewis EF; Solomon SD; Parving HH; Pfeffer M; McMurray JJ; Rossing P;
J Hum Hypertens; 2016 Jan; 30(1):46-52. PubMed ID: 25810068
[TBL] [Abstract][Full Text] [Related]
51. Epoetins and [symbol: see text] darbepoetin alfa in malignant disease.
Drug Ther Bull; 2004 Mar; 42(3):21-3. PubMed ID: 15038080
[TBL] [Abstract][Full Text] [Related]
52. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
Pfeffer MA; Burdmann EA; Chen CY; Cooper ME; de Zeeuw D; Eckardt KU; Feyzi JM; Ivanovich P; Kewalramani R; Levey AS; Lewis EF; McGill JB; McMurray JJ; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto R;
N Engl J Med; 2009 Nov; 361(21):2019-32. PubMed ID: 19880844
[TBL] [Abstract][Full Text] [Related]
53. Long-term mortality and retinopathy in type 1 diabetes.
Grauslund J
Acta Ophthalmol; 2010 May; 88 Thesis1():1-14. PubMed ID: 20500731
[TBL] [Abstract][Full Text] [Related]
54. [Effects of dose of erythropoiesis stimulating agents on cardiovascular outcomes, quality of life and costs of haemodialysis. the clinical evaluation of the DOSe of erythropoietins (C.E. DOSE) Trial].
Saglimbene V; D'Alonzo D; Ruospo M; Vecchio M; Natale P; Gargano L; Nicolucci A; Pellegrini F; Craig JC; Triolo G; Procaccini DA; Santoro A; Di Giulio S; La Rosa S; Murgo A; Di Toro Mammarella R; Sambati M; D'Ambrosio N; Greco V; Giannoccaro G; Flammini A; Boccia E; Montalto G; Pagano S; Amarù S; Fici M; Lumaga GB; Mancini E; Veronesi M; Patregnani L; Querques M; Schiavone P; Chimienti S; Palumbo R; Di Franco D; Della Volpe M; Gori E; Salomone M; Iacono A; Moscoloni M; Treglia A; Casu D; Piras AM; Di Silva A; Mandreoli M; Lopez A; Quarello F; Catizone L; Russo G; Forcellini S; Maccarone M; Catucci G; Di Paolo B; Stingone A; D'Angelo B; Guastoni C; Pasquali S; Minoretti C; Bellasi A; Boscutti G; Martone M; David S; Schito F; Urban L; Di Iorio B; Caruso F; Mazzoni A; Musacchio R; Andreoli D; Cossu M; Li Cavoli G; Cornacchiari M; Granata A; Clementi A; Giordano R; Guastoni C; Barzaghi W; Valentini M; Hegbrant J; Tognoni G; Strippoli GF
G Ital Nefrol; 2013; 30(2):. PubMed ID: 23832463
[TBL] [Abstract][Full Text] [Related]
55. Diabetic microvascular complications: can patients at risk be identified? A review.
Girach A; Manner D; Porta M
Int J Clin Pract; 2006 Nov; 60(11):1471-83. PubMed ID: 17073842
[TBL] [Abstract][Full Text] [Related]
56. Erythropoietin deficiency and relative resistance cause anaemia in post-renal transplant recipients with normal renal function.
Nampoory MR; Johny KV; al-Hilali N; Seshadri MS; Kanagasabhapathy AS
Nephrol Dial Transplant; 1996 Jan; 11(1):177-81. PubMed ID: 8649630
[TBL] [Abstract][Full Text] [Related]
57. Nephropathy, but not retinopathy, is associated with the development of heart disease in Type 1 diabetes: a 12-year observation study of 462 patients.
Torffvit O; Lövestam-Adrian M; Agardh E; Agardh CD
Diabet Med; 2005 Jun; 22(6):723-9. PubMed ID: 15910623
[TBL] [Abstract][Full Text] [Related]
58. Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA).
Goldsmith D; Covic A
Nephrol Dial Transplant; 2010 Jun; 25(6):1734-7. PubMed ID: 20200007
[No Abstract] [Full Text] [Related]
59. Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).
Schutte E; Lambers Heerspink HJ; Lutgers HL; Bakker SJ; Vart P; Wolffenbuttel BH; Umanath K; Lewis JB; de Zeeuw D; Gansevoort RT
Am J Kidney Dis; 2015 Sep; 66(3):450-8. PubMed ID: 25987260
[TBL] [Abstract][Full Text] [Related]
60. Anemia in diabetes: marker or mediator of microvascular disease?
Thomas MC
Nat Clin Pract Nephrol; 2007 Jan; 3(1):20-30. PubMed ID: 17183259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
